#cell viability

[oaresearchpaper]

The present study focused on the extraction, purification, and characterization of proteins from seeds of Vitis vinifera and Mangifera indica, along with evaluation of their anti-proliferative potential. Protein estimation using the Lowry method revealed higher protein content in grape seed extract (4.98 ± 0.14 mg/mL) compared to mango seed extract (4.20 ± 0.12 mg/mL). Spectrophotometric analysis at 280 nm showed higher absorbance for grape seed protein (1.32 ± 0.05) than mango seed protein (1.08 ± 0.04), confirming greater protein abundance. SDS-PAGE profiling indicated multiple protein bands in the range of 30–97 kDa for grape seeds and 35–80 kDa for mango seeds, with grape seed proteins exhibiting greater molecular diversity. The anti-proliferative activity of the purified proteins was assessed using the MTT assay against HeLa and MCF-7 cancer cell lines. A dose-dependent decrease in cell viability was observed, with HeLa cells showing higher sensitivity (IC₅₀ ≈ 120 µg/mL) compared to MCF-7 cells (IC₅₀ ≈ 135 µg/mL). At 200 µg/mL, cell viability decreased to 29.5% in HeLa and 35.0% in MCF-7 cells. Morphological assessment uses light microscopy and acridine orange/ethidium bromide staining revealed characteristic apoptotic features, including cell shrinkage, membrane blebbing, chromatin condensation, and nuclear fragmentation, confirming apoptosis as the primary mechanism of cell death. Overall, the results indicate that grape seed proteins possess higher protein content, greater structural complexity, and stronger anti-proliferative activity compared to mango seed proteins. These findings highlight the potential of seed-derived proteins as promising natural candidates for anticancer applications and support further investigation into their molecular mechanisms.

[harrywilliam0100]

American Cell Technology Building a Foundation for Future Cellular and Regenerative Medicine

American Cell Technology is a specialized organization focused on long-term stem cell preservation and cellular storage solutions in the United States. The company supports individuals and families who wish to protect their own biological material for future medical possibilities. As healthcare continues to shift toward personalized and regenerative medicine, stem cell banking has become an increasingly important part of proactive health planning.

The organization’s core objective is to maintain high-quality, viable stem cells under controlled conditions so they remain accessible as scientific research and medical applications evolve.

Stem Cells and Their Medical Significance

Stem cells are fundamental building blocks of the human body, known for their ability to self-renew and support tissue regeneration. These cells are actively studied in regenerative medicine due to their potential role in supporting cellular repair and recovery.

Preserving stem cells at an early stage allows individuals to maintain access to their own genetically compatible cells, eliminating compatibility challenges and reducing reliance on donor-based materials. This personalized approach aligns with the future direction of medical care.

Approach to Stem Cell Collection and Storage

American Cell Technology follows a structured and quality-driven process for stem cell preservation:

Collection and Processing Stem cells are carefully collected from approved sources and processed using controlled laboratory techniques to maintain cellular integrity.

Cryogenic Preservation Cells are preserved at ultra-low temperatures, a method designed to protect cell structure, DNA stability, and long-term viability.

Secure Long-Term Storage Ongoing monitoring ensures that stored cells remain protected and retrievable when needed for future medical consultation.

This approach emphasizes consistency, safety, and reliability throughout the preservation lifecycle.

Stem Cell Banking as Part of Preventive Health Planning

Stem cell banking is not a medical treatment but rather a strategic health decision. By preserving stem cells today, individuals create future opportunities to participate in emerging regenerative therapies, subject to medical guidance and regulatory approval.

As research into mesenchymal stem cells (MSCs) continues to expand, having preserved cells provides flexibility and preparedness for potential applications across various areas of medicine.

Advantages of Personal Stem Cell Preservation

Choosing to preserve stem cells offers several long-term benefits:

Lifelong access to personal, genetically matched stem cells

Enhanced preparedness for advances in regenerative medicine

Reduced dependency on donor-derived cellular materials

Support for personalized medical decision-making

Peace of mind through proactive biological planning

American Cell Technology emphasizes responsible preservation and scientific standards, ensuring stored cells remain a valuable medical resource.

Quality Assurance and Scientific Responsibility

American Cell Technology maintains strict standards for laboratory practices, quality assurance, and regulatory compliance. Each stage of the preservation process is designed to protect cellular quality while maintaining traceability and security.

The organization’s focus on scientific responsibility ensures that preserved stem cells meet high standards for future medical consideration.

Looking Ahead: The Role of Cellular Preservation

As medical science advances, the demand for personalized and regenerative healthcare solutions is expected to grow. Stem cell preservation provides individuals with a practical way to prepare for these advancements while maintaining control over their own biological resources.

American Cell Technology supports this forward-looking approach by offering dependable, long-term cellular preservation services rooted in science and quality.

Conclusion

American Cell Technology contributes to the future of healthcare by supporting personal stem cell preservation and cellular readiness. Through structured preservation methods, quality-controlled storage, and a commitment to scientific standards, the organization enables individuals and families to prepare for the next generation of medical innovation.

By safeguarding cellular health today, American Cell Technology helps build a foundation for tomorrow’s regenerative and personalized medical possibilities.

[oaresearchpaper]

Turbinaria ornata is a species of marine brown seaweed and in the family Sargassaceae. They were freshly collected from Mandapam Coastal Area, Rameswaram Tamil Nadu, India and rinsed in seawater and packed in sterile bags for further proceedings to laboratory. Seaweeds have the potential to be utilized as renewable resources within the marine environment. An invitro study of Turbinaria ornata in cell lines were human HepG2 hepatic carcinoma cells, liver cancer cell line HepG2 preserved in RPMI-1640 medium at 37 °C Turbunaria ornata ethanolic extract (TOE) using cell viability assay and cytotoxic effect (Brown sea weed), The effect of TOE and standard anticancer drug Doxorubicin (DOX) (1µm/ml) on cell growth inhibition was assessed as percent cell viability where vehicle-treated cells were taken as 100% viable. The supernatant was removed and 50 µl of propanol was added and the plates were gently shaken to solubilize the formed formazan, MTT assay of yellow 3-(4, 5dimethythiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) HepG2 cells and treated with various concentration of TOE (25-200 μg/ml) and standard doxorubicin (1µm) for 24h. The half maximal inhibitory concentration (IC50) of TOE as the percentage survival of the cells. The fluorescence microscopy images of the untreated HepG2 cells (A). HepG2 cells treated with TOE (100µg) (B), TOE (200µg) (C) and DOX (D) for 24 hours. In the DAIP Staining, the yellow arrows indicate intact nucleus, green arrows, mitotic cells and the red arrows show the apoptotic cells. TOE at 100 and 200 μg showed apoptosis on HepG2 cells, which may in part account for the anticancer activity.

[oaresearchpaper]

Anticancer Potential of Turbinaria ornata: Insights from Cytotoxicity Assays

Turbinaria ornata is a species of marine brown seaweed and in the family Sargassaceae. They were freshly collected from Mandapam Coastal Area, Rameswaram Tamil Nadu, India and rinsed in seawater and packed in sterile bags for further proceedings to laboratory. Seaweeds have the potential to be utilized as renewable resources within the marine environment. An invitro study of Turbinaria ornata in cell lines were human HepG2 hepatic carcinoma cells, liver cancer cell line HepG2 preserved in RPMI-1640 medium at 37 °C Turbunaria ornata ethanolic extract (TOE) using cell viability assay and cytotoxic effect (Brown sea weed), The effect of TOE and standard anticancer drug Doxorubicin (DOX) (1µm/ml) on cell growth inhibition was assessed as percent cell viability where vehicle-treated cells were taken as 100% viable. The supernatant was removed and 50 µl of propanol was added and the plates were gently shaken to solubilize the formed formazan, MTT assay of yellow 3-(4, 5dimethythiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) HepG2 cells and treated with various concentration of TOE (25-200 μg/ml) and standard doxorubicin (1µm) for 24h. The half maximal inhibitory concentration (IC50) of TOE as the percentage survival of the cells. The fluorescence microscopy images of the untreated HepG2 cells (A). HepG2 cells treated with TOE (100µg) (B), TOE (200µg) (C) and DOX (D) for 24 hours. In the DAIP Staining, the yellow arrows indicate intact nucleus, green arrows, mitotic cells and the red arrows show the apoptotic cells. TOE at 100 and 200 μg showed apoptosis on HepG2 cells, which may in part account for the anticancer activity.

[oaresearchpaper]

Anticancer Potential of Turbinaria ornata: Insights from Cytotoxicity Assays | InformativeBD

Turbinaria ornata is a species of marine brown seaweed and in the family Sargassaceae. They were freshly collected from Mandapam Coastal Area, Rameswaram Tamil Nadu, India and rinsed in seawater and packed in sterile bags for further proceedings to laboratory. Seaweeds have the potential to be utilized as renewable resources within the marine environment. An invitro study of Turbinaria ornata in cell lines were human HepG2 hepatic carcinoma cells, liver cancer cell line HepG2 preserved in RPMI-1640 medium at 37 °C Turbunaria ornata ethanolic extract (TOE) using cell viability assay and cytotoxic effect (Brown sea weed), The effect of TOE and standard anticancer drug Doxorubicin (DOX) (1µm/ml) on cell growth inhibition was assessed as percent cell viability where vehicle-treated cells were taken as 100% viable. The supernatant was removed and 50 µl of propanol was added and the plates were gently shaken to solubilize the formed formazan, MTT assay of yellow 3-(4, 5dimethythiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) HepG2 cells and treated with various concentration of TOE (25-200 μg/ml) and standard doxorubicin (1µm) for 24h. The half maximal inhibitory concentration (IC50) of TOE as the percentage survival of the cells. The fluorescence microscopy images of the untreated HepG2 cells (A). HepG2 cells treated with TOE (100µg) (B), TOE (200µg) (C) and DOX (D) for 24 hours. In the DAIP Staining, the yellow arrows indicate intact nucleus, green arrows, mitotic cells and the red arrows show the apoptotic cells. TOE at 100 and 200 μg showed apoptosis on HepG2 cells, which may in part account for the anticancer activity.

[mbimphblog]

EVALUATION OF CYTOTOXICITY AND ANTI-CANCER ACTIVITY OF Solanum torvum STEM EXTRACT ON NORMAL VERO AND HUMAN BREAST CANCER MCF - 7 CELL LINE | UTTAR PRADESH JOURNAL OF ZOOLOGY

Limited plants have been screened for their complete biological and pharmacological nature. In the present research investigation an attempt was made to decipher the medicinal value of aqueous extract of Solanum torvum (S.torvum) stem. Phytochemical screening of the aqueous extract of S.torvum stem in the present study ascertain the presence of flavonoids, phenols, saponins, alkaloids, coumarins, sterols, proteins and reducing sugars. Further, the potentiality of aqueous extract of S.torvum stem was assessed for its cytotoxic effect on Normal Vero cell line and anticancer activity on Human breast adenocarcinoma cell line by 3-(4,5dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide assay and compared with normal drug target doxorubicin. A 24-hour incubation cell proliferation study reduced the cell viability of MCF-7 breast cancer cell lines. In vitro studies on cytotoxicity analysis on Vero cell line revealed that the aqueous stem extract of S.torvum show mild toxicity and further it was found to be effective in the prevention of cell proliferation by MCF-7 cell lines. Please see the link :- https://mbimph.com/index.php/UPJOZ/article/view/2111

[jppres]

In vitro anti-aging activity of Muntingia calabura L. fruit extract and its fractions

In vitro anti-aging activity of Muntingia calabura L. fruit extract and its fractions

Image: Wikimedia Article published in the Journal of Pharmacy & Pharmacognosy Research 9(4): 409-421, 2021. Original article Syamsu Nur1*, Aprilia Angreiny Angelina1, Muhammad Aswad2, Risfah Yulianty2, Asril Burhan1, Nursamsiar1 1Department of Pharmaceutical Chemistry, Sekolah Tinggi Ilmu Farmasi, Makassar, 90242, Indonesia. 2Pharmacy Faculty, Hasanuddin University, Makassar, 90242,…

View On WordPress

[maddyslensecraft]

Leading Players in the Global Cell Viability Assays Market

The global cell viability assays market is projected to reach USD 4.16 billion by 2023 from USD 2.78 billion in 2018, at a CAGR of 8.4%.  Factors such as rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research and rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics are driving the growth of this market. The emerging markets are expected to provide growth opportunities for players operating in the cell viability assays market in the coming years.  However, the high cost of instruments is expected to restrain the growth of this market to a certain extent during the forecast period. Players in the global cell viability assays market, such as Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), GE Healthcare (US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), G-Biosciences (US), Creative Bioarray (US), Danaher Corporation (US), and Becton, Dickinson and Company (US), are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies of product launches, expansions, agreements, collaborations, and acquisitions. Download PDF Brochure@  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=5932511 Thermo Fisher is the leading player in the cell viability assay kits market. The company offers a broad portfolio of cell viability assays for flow cytometers, microplates, biofilm imaging, along with other consumables ranging from reagents to stains and dyes. The company’s stronghold in the market is largely due to its strong product portfolio and strong customer relations and its strong sales and distribution network. It also leverages the advantage of three well-established brands Thermo Scientific, Fisher Scientific, and Unity Lab Services. Additionally, its large number of production sites gives it a competitive advantage over other players in the cell viability assays market. The company’s extensive R&D activities enable it to increase its depth of capabilities in technologies, software, and services. Moreover, its significant investments in R&D enable it to provide innovative products in the market space, thus enabling it to maintain and improve its competitive position in the cell analysis market. The company’s FDA and CE Mark-approved products have helped it to further enhance its presence in this market. Thermo Fisher also focuses on geographic expansions. In line with this, the firm opened new GMP facilities in the US and South Korea in 2016. Moreover, the company aims to strengthen its presence in selected geographies in the Asia Pacific region, undertaking various organic and inorganic growth strategies. Target Audience: # Manufacturers of cell viability instruments and consumables # Distributors of cell viability instruments and consumables # Research and development organizations # Hospitals and clinics # Diagnostic centers # Market research and consulting firms # Venture capitalists and investors Merck is the second-largest player in the global cell viability assay kits market in 2018. With a strong brand name and wide geographic coverage in more than 60 countries, Merck has a well-established presence in this market. This company is expected to witness high growth in this market by adopting various organic and inorganic growth strategies. With regard to providing innovative products, Merck invests a significant amount of its sales revenue in R&D. In 2017, it invested around 14% of its sales revenue into R&D.  This allows the company to extend its technological capabilities and provide superior-quality products, thereby helping it to achieve long-term growth. The company is also investing a large sum in its expansion projects to increase its production capacity and cater to a larger consumer base. In this regard, the company invested USD 19 million in its new manufacturing and distribution center for the Life Science business in India, in 2018. Similar investments have been made by the company in the last few years. The acquisition of Sigma-Aldrich significantly enhanced the company’s global presence and broadened its portfolio in the cell viability assays market. Request Sample Pages@  https://www.marketsandmarkets.com/requestsampleNew.asp?id=5932511 By end user, the pharmaceutical and biotechnology companies segment is estimated to hold the largest share of the cell viability assays market in 2018 On the basis of end user, the cell viability assays market is segmented into pharmaceutical and biotechnology companies, hospital and diagnostic laboratories, academic and research institutes, and other end users (food and beverage companies and environmental testing companies). The pharmaceutical and biotechnology companies segment is expected to account for the largest share in 2018. The large share of this segment can be attributed to the increasing number of R&D activities undertaken by these companies for the development of biopharmaceutical products. North America to dominate the market in 2018 North America is expected to account for the largest share of the cell viability assays market in 2018, followed by Europe and Asia Pacific. The growing incidence rate of various infectious diseases, investment initiatives by the government, and the high-quality infrastructure for clinical and laboratory research are the major factors responsible for the large share of the North American cell viability assays market. Moreover, a number of major global players are based in the US, owing to which, the US is a center for innovation in the cell viability assays market.